Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis
Abstract Psilocybin-assisted therapy (PAT) has been shown in early trials to reduce the symptoms of treatment-resistant depression (TRD). This study evaluated the cost-effectiveness of PAT as a third-line treatment for major depressive disorder compared to standard of care (SOC). We used an individu...
| 出版年: | Translational Psychiatry |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | 論文 |
| 言語: | 英語 |
| 出版事項: |
Nature Publishing Group
2025-08-01
|
| オンライン･アクセス: | https://doi.org/10.1038/s41398-025-03556-4 |